BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 9425057)

  • 1. Human testis-determining factor SRY binds to the major DNA adduct of cisplatin and a putative target sequence with comparable affinities.
    Trimmer EE; Zamble DB; Lippard SJ; Essigmann JM
    Biochemistry; 1998 Jan; 37(1):352-62. PubMed ID: 9425057
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Binding of tsHMG, a mouse testis-specific HMG-domain protein, to cisplatin-DNA adducts.
    Ohndorf UM; Whitehead JP; Raju NL; Lippard SJ
    Biochemistry; 1997 Dec; 36(48):14807-15. PubMed ID: 9398202
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Binding of Ixr1, a yeast HMG-domain protein, to cisplatin-DNA adducts in vitro and in vivo.
    McA'Nulty MM; Whitehead JP; Lippard SJ
    Biochemistry; 1996 May; 35(19):6089-99. PubMed ID: 8634251
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DNA sequence context and protein composition modulate HMG-domain protein recognition of cisplatin-modified DNA.
    Dunham SU; Lippard SJ
    Biochemistry; 1997 Sep; 36(38):11428-36. PubMed ID: 9298962
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Basis for recognition of cisplatin-modified DNA by high-mobility-group proteins.
    Ohndorf UM; Rould MA; He Q; Pabo CO; Lippard SJ
    Nature; 1999 Jun; 399(6737):708-12. PubMed ID: 10385126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A single HMG domain in high-mobility group 1 protein binds to DNAs as small as 20 base pairs containing the major cisplatin adduct.
    Chow CS; Barnes CM; Lippard SJ
    Biochemistry; 1995 Mar; 34(9):2956-64. PubMed ID: 7893709
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nature of full-length HMGB1 binding to cisplatin-modified DNA.
    Jung Y; Lippard SJ
    Biochemistry; 2003 Mar; 42(9):2664-71. PubMed ID: 12614161
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recognition and repair of DNA-cisplatin adducts.
    Woźniak K; Błasiak J
    Acta Biochim Pol; 2002; 49(3):583-96. PubMed ID: 12422229
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cisplatin-DNA adducts inhibit ribosomal RNA synthesis by hijacking the transcription factor human upstream binding factor.
    Zhai X; Beckmann H; Jantzen HM; Essigmann JM
    Biochemistry; 1998 Nov; 37(46):16307-15. PubMed ID: 9819223
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Photoreactivity of platinum(II) in cisplatin-modified DNA affords specific cross-links to HMG domain proteins.
    Kane SA; Lippard SJ
    Biochemistry; 1996 Feb; 35(7):2180-8. PubMed ID: 8652559
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNA sequence context modulates the impact of a cisplatin 1,2-d(GpG) intrastrand cross-link on the conformational and thermodynamic properties of duplex DNA.
    Pilch DS; Dunham SU; Jamieson ER; Lippard SJ; Breslauer KJ
    J Mol Biol; 2000 Feb; 296(3):803-12. PubMed ID: 10677282
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural basis for SRY-dependent 46-X,Y sex reversal: modulation of DNA bending by a naturally occurring point mutation.
    Murphy EC; Zhurkin VB; Louis JM; Cornilescu G; Clore GM
    J Mol Biol; 2001 Sep; 312(3):481-99. PubMed ID: 11563911
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cisplatin-DNA binding specificity of calf high-mobility group 1 protein.
    Turchi JJ; Li M; Henkels KM
    Biochemistry; 1996 Mar; 35(9):2992-3000. PubMed ID: 8608137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recognition of DNA interstrand cross-link of antitumor cisplatin by HMGB1 protein.
    Kasparkova J; Delalande O; Stros M; Elizondo-Riojas MA; Vojtiskova M; Kozelka J; Brabec V
    Biochemistry; 2003 Feb; 42(5):1234-44. PubMed ID: 12564926
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HMG1 protein inhibits the translesion synthesis of the major DNA cisplatin adduct by cell extracts.
    Hoffmann JS; Locker D; Villani G; Leng M
    J Mol Biol; 1997 Jul; 270(4):539-43. PubMed ID: 9245584
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human replication protein A preferentially binds cisplatin-damaged duplex DNA in vitro.
    Patrick SM; Turchi JJ
    Biochemistry; 1998 Jun; 37(24):8808-15. PubMed ID: 9628743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Crystal structure of double-stranded DNA containing the major adduct of the anticancer drug cisplatin.
    Takahara PM; Rosenzweig AC; Frederick CA; Lippard SJ
    Nature; 1995 Oct; 377(6550):649-52. PubMed ID: 7566180
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interaction between cisplatin-modified DNA and the HMG boxes of HMG 1: DNase I footprinting and circular dichroism.
    Locker D; Decoville M; Maurizot JC; Bianchi ME; Leng M
    J Mol Biol; 1995 Feb; 246(2):243-7. PubMed ID: 7869375
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sry-directed sex reversal in transgenic mice is robust with respect to enhanced DNA bending: comparison of human and murine HMG boxes.
    Phillips NB; Nikolskaya T; Jancso-Radek A; Ittah V; Jiang F; Singh R; Haas E; Weiss MA
    Biochemistry; 2004 Jun; 43(22):7066-81. PubMed ID: 15170344
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HMG-domain protein recognition of cisplatin 1,2-intrastrand d(GpG) cross-links in purine-rich sequence contexts.
    Cohen SM; Mikata Y; He Q; Lippard SJ
    Biochemistry; 2000 Sep; 39(38):11771-6. PubMed ID: 10995245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.